A difluorinated inhibitor showed 4.23 times larger potency against the epidermal growth factor receptor (EGFR) than a nonfluorinated inhibitor [22]mutations of which have been linked specifically to nonsmall-cell lung cancer. Here, EGFR is linked to lung cancer.